Obesity (Silver Spring, Md.)最新文献

Response to Dodd et al.: contextualizing pregnancy weight research within clinical and public health practice. 对 Dodd 等人的回应：在临床和公共卫生实践中开展孕期体重研究。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-05 DOI: 10.1002/oby.24170

Janne Boone-Heinonen, Jonathan M Snowden, Kimberly K Vesco, Erin S LeBlanc, Teresa Schmidt, Rachel Springer

引用次数: 0

Planning laws as part of a systems approach are needed to improve children's health and reduce inequalities. 需要将规划法作为系统方法的一部分，以改善儿童健康状况并减少不平等现象。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-05 DOI: 10.1002/oby.24165

Shu Wen Ng, Christina Vogel

引用次数: 0

Obesity (Silver Spring, Md.) Pub Date : 2024-11-05 DOI: 10.1002/oby.24143

Yanfang Guo, Sara C S Souza, Liam Bruce, Rong Luo, Darine El-Chaâr, Laura M Gaudet, Katherine Muldoon, Steven Hawken, Sandra I Dunn, Ruth Rennicks White, Alysha L J Dingwall-Harvey, Mark C Walker, Shi Wu Wen, Daniel J Corsi

{"title":"Risk related to gestational weight loss among individuals with obesity: a population-based cohort study.","authors":"Yanfang Guo, Sara C S Souza, Liam Bruce, Rong Luo, Darine El-Chaâr, Laura M Gaudet, Katherine Muldoon, Steven Hawken, Sandra I Dunn, Ruth Rennicks White, Alysha L J Dingwall-Harvey, Mark C Walker, Shi Wu Wen, Daniel J Corsi","doi":"10.1002/oby.24143","DOIUrl":"https://doi.org/10.1002/oby.24143","url":null,"abstract":"Objective: There is no clear evidence on the risk of gestational weight loss (GWL) for individuals with obesity. Our study aimed to assess the association between GWL and adverse perinatal outcomes among individuals with obesity.Methods: This population-based retrospective cohort study examined individuals with prepregnancy BMI ≥ 30 kg/m2 who had a singleton pregnancy, using Ontario, Canada, birth registry data from 2012 to 2020. The primary outcome was a composite of adverse outcomes, including perinatal death and neonatal morbidity. The association between GWL and risk of adverse perinatal outcomes was estimated using generalized estimating equation models and restricted cubic spline regression analysis. Stratified analysis was conducted by obesity class.Results: Of the 157,205 individuals with obesity, 6.1% experienced GWL. Compared with adequate gestational weight gain, GWL was associated with an increased risk of a composite of adverse perinatal outcomes (adjusted risk ratio: 1.31; 95% CI: 1.22-1.39). Similar results were observed in the stratified analysis. Restricted cubic spline regression analysis revealed that average weekly gestational weight changes displayed a nonlinear U-shaped association, with a higher risk of a composite of adverse perinatal outcomes noted in the extremities, particularly toward GWL and excessive weight gain.Conclusions: Our findings suggest that GWL may increase the risk of adverse perinatal outcomes across all obesity classes.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142585060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unpacking the (more accepted) role of the dental team in obesity. 解读牙科团队在肥胖症中的作用（更多被接受）。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-05 DOI: 10.1002/oby.24171

Zanab Malik, Kathryn Williams, Deborah Cockrell, Clare E Collins

引用次数: 0

Changes in anthropometry, adiposity, and inflammation in Black and White women engaged in intentional weight loss. 有意减肥的黑人和白人女性在人体测量、脂肪和炎症方面的变化。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-04 DOI: 10.1002/oby.24151

Ashley S Felix, Jennifer A Sinnott, Bette J Caan, Shannon L Gillespie, Caitlin E Meade, Katherine E Strafford, Casey M Cosgrove, Loriana Soma, Sabrena Noria, Kristin L Bixel, Ritu Salani, Christa I Nagel, Laura M Chambers, David E Cohn, Adrian A Suarez, Electra D Paskett

{"title":"Changes in anthropometry, adiposity, and inflammation in Black and White women engaged in intentional weight loss.","authors":"Ashley S Felix, Jennifer A Sinnott, Bette J Caan, Shannon L Gillespie, Caitlin E Meade, Katherine E Strafford, Casey M Cosgrove, Loriana Soma, Sabrena Noria, Kristin L Bixel, Ritu Salani, Christa I Nagel, Laura M Chambers, David E Cohn, Adrian A Suarez, Electra D Paskett","doi":"10.1002/oby.24151","DOIUrl":"https://doi.org/10.1002/oby.24151","url":null,"abstract":"Objective: We examined associations among changes in anthropometry, regional adiposity, and inflammatory markers in Black and White women participating in intentional weight loss.Methods: A total of 104 women with BMI ≥ 25 kg/m2 self-selected bariatric surgery (n = 66) or a diet and exercise program (n = 38). Anthropometric, dual-energy x-ray absorptiometry-quantified regional adiposity, and inflammatory markers (C-reactive protein [CRP], tumor necrosis factor α [TNF-α], soluble TNF receptor I [sTNFRI], sTNFRII, interleukin [IL]-6, and soluble IL-1 receptor antagonist) were measured at baseline and 6 months.Results: Weight, BMI, visceral adipose tissue, and regional (android and gynoid) adiposity declined in the bariatric surgery group. Among bariatric surgery participants, Black women experienced declines of lesser magnitude in terms of weight and BMI than White women, but changes in regional adiposity and visceral adipose tissue did not differ. In the bariatric surgery group, decreases in weight and BMI were associated with decreases in CRP and IL-6 among White women, but not Black women. Decreases in weight, BMI, and android fat were associated with increases in TNF-α, sTNFRI, and sTNFRII among Black women, but not White women.Conclusions: Decreases in anthropometry and adiposity were observed among Black and White bariatric surgery participants; however, associations among changes in adiposity, anthropometry, and inflammation differed by race.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The safety of semaglutide in patients with depression and obesity. 在抑郁症和肥胖症患者中使用semaglutide的安全性。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-04 DOI: 10.1002/oby.24142

Ziyi Yang, Yimin Yan

引用次数: 0

Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity. 饮食诱发肥胖症中脂肪源性干细胞的部位特异性差异和异质性。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-04 DOI: 10.1002/oby.24149

Honglin Guo, Ailing Sheng, Xiangyu Qi, Lin Zhu, Guanyu Wang, Yizhou Zou, Qingbo Guan, Yuntao Lu, Hui Tang, Xu Hou

{"title":"Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity.","authors":"Honglin Guo, Ailing Sheng, Xiangyu Qi, Lin Zhu, Guanyu Wang, Yizhou Zou, Qingbo Guan, Yuntao Lu, Hui Tang, Xu Hou","doi":"10.1002/oby.24149","DOIUrl":"https://doi.org/10.1002/oby.24149","url":null,"abstract":"Objective: Obesity is a global health concern. Studying the heterogeneity of adipose-derived stem cells (ADSCs) plays a pivotal role in understanding metabolic disorders, such as obesity.Methods: Mass cytometry was used to determine the depot-specific differences and heterogeneity of ADSCs and their alterations at the single-cell level in a diet-induced-obesity (DIO) model in which mice were treated with liraglutide.Results: We characterized the relationship among ADSC markers and found that CD26 and CD142 could identify the most representative heterogeneous ADSCs in subcutaneous adipose tissue and visceral adipose tissue. Specifically, CD26+CD142- and CD26+CD142+ ADSCs were exclusive to subcutaneous adipose tissue and visceral adipose tissue, respectively, whereas CD26-CD142+ ADSCs were present in both. RNA analysis explored the potential functions of these three subgroups. In the visceral adipose tissue of DIO mice, we observed a substantial downregulation of CD26+CD142+ ADSCs and upregulation of CD26-CD142+ ADSCs, both of which were mitigated by liraglutide treatment.Conclusions: Our study highlights the depot-specific differences and heterogeneity of ADSCs and their alterations under DIO conditions, which can potentially be reversed by liraglutide treatment. This study provides new insights into the identification of more specific ADSC subgroups to explore the etiology of metabolism-related diseases.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to "The safety of semaglutide in patients with depression and obesity". 对 "抑郁症和肥胖症患者使用塞马鲁肽的安全性 "的回应。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-04 DOI: 10.1002/oby.24144

Robert F Kushner, Thomas A Wadden

引用次数: 0

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). 苏伐度肽治疗肥胖症：两项随机三期临床试验（SYNCHRONIZE™-1 和 -2）的原理和设计。

Obesity (Silver Spring, Md.) Pub Date : 2024-11-04 DOI: 10.1002/oby.24184

Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, Elke Platz, Martina Brueckmann, Ania M Jastreboff, Samina Ajaz Hussain, Sue D Pedersen, Luiza Borowska, Anna Unseld, Isabel M Kloer, Lee M Kaplan

{"title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).","authors":"Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, Elke Platz, Martina Brueckmann, Ania M Jastreboff, Samina Ajaz Hussain, Sue D Pedersen, Luiza Borowska, Anna Unseld, Isabel M Kloer, Lee M Kaplan","doi":"10.1002/oby.24184","DOIUrl":"https://doi.org/10.1002/oby.24184","url":null,"abstract":"Objective: The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE-1 and -2).Methods: In these ongoing double-blind trials, participants were randomized to once-weekly subcutaneous injections of survodutide or placebo added to lifestyle modification. Survodutide doses are uptitrated to 3.6 or 6.0 mg, and dose flexibility is permitted. Participants (n = 726) in SYNCHRONIZE-1 (NCT06066515) have a baseline BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication but without T2D; participants (n = 755) in SYNCHRONIZE-2 (NCT06066528) have a baseline BMI ≥ 27 kg/m2 and T2D. The primary endpoints are percentage change in body weight and proportion of participants achieving ≥5% body weight reduction from baseline to week 76. Secondary endpoints include change in systolic blood pressure and measures of glycemia. A SYNCHRONIZE-1 substudy is evaluating changes in body composition and liver fat content using magnetic resonance imaging.Conclusions: These trials are designed to provide robust evaluation of the efficacy, safety, and tolerability of survodutide for the treatment of obesity in the presence or absence of T2D.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications. 对远程保健肥胖症治疗提供商使用抗肥胖症药物进行为期 12 个月的实际证据分析。

Obesity (Silver Spring, Md.) Pub Date : 2024-10-30 DOI: 10.1002/oby.24169

Jamy D Ard, Young-Rock Hong, Gary D Foster, Adam Medcalf, Spencer Nadolsky, Michelle I Cardel

{"title":"Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications.","authors":"Jamy D Ard, Young-Rock Hong, Gary D Foster, Adam Medcalf, Spencer Nadolsky, Michelle I Cardel","doi":"10.1002/oby.24169","DOIUrl":"https://doi.org/10.1002/oby.24169","url":null,"abstract":"Objective: The objective of this study was to describe weight changes in members of a large-scale telehealth obesity-treatment provider who were using antiobesity medications (AOMs).Methods: This retrospective observational study analyzed real-world data from adults who initiated AOM treatment with the WW International, Inc. (formerly Weight Watchers) Clinic telehealth program between January 2022 and July 2023 (n = 53,590). The main outcomes were changes in body weight over 12 months, side effects over follow-up, and medication usage patterns.Results: The 53,590 patients who initiated treatment were predominantly female (88.6%), with a mean BMI of 36.9 kg/m2. Mean (SD) treatment duration was 5.3 (4.3) months. Program retention rates based on the number of patients whose time from enrollment was at least 3, 6, 9, and 12 months were 78% (n = 39,907/51,247), 63% (n = 25,515/40,203), 58% (n = 15,472/26,794), and 77% (n = 6459/8394), respectively. Average weight loss was 8.9% at 3 months (n = 37,565), 14.1% at 6 months (n = 24,140), 17.7% at 9 months (n = 15,169), and 19.4% at 12 months (n = 6089). Glucagon-like peptide-1 receptor agonist (GLP-1-RA)-based treatments were predominant. Side effects were consistent with the classes of medications used, and frequency declined over time.Conclusions: This real-world analysis of a telehealth-delivered obesity-treatment program demonstrated outcomes consistent with recent phase 3 clinical trials of AOMs, suggesting generalizability beyond clinical trial and in-person settings.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0